Press Releases | BioSenic

Bone Therapeutics Provides Business Update for the First Quarter 2015

Read more about Bone Therapeutics Provides Business Update for the First Quarter 2015

Bone Therapeutics reports first results of its Phase IIA trial for PREOB® in severe osteoporosis

Read more about Bone Therapeutics reports first results of its Phase IIA trial for PREOB® in severe osteoporosis

Bone Therapeutics treats second patient cohort in ALLOB® Phase I/IIA delayed-union fracture trial

Read more about Bone Therapeutics treats second patient cohort in ALLOB® Phase I/IIA delayed-union fracture trial

Bone Therapeutics Notice of Half Year Results 2015

Read more about Bone Therapeutics Notice of Half Year Results 2015

Bone Therapeutics announces half-year results for 2015

Read more about Bone Therapeutics announces half-year results for 2015

Bone Therapeutics treats first patients in pioneering trial for minimally invasive treatment of failed spinal fusion

Read more about Bone Therapeutics treats first patients in pioneering trial for minimally invasive treatment of failed spinal fusion

Bone Therapeutics to participate in key investor conferences in Q4 2015

Read more about Bone Therapeutics to participate in key investor conferences in Q4 2015

Transparency notification received from S.R.I.W. SA & Sofipôle SA

Read more about Transparency notification received from S.R.I.W. SA & Sofipôle SA

Bone Therapeutics Appoints Thomas Lienard as Chief Business Officer

Read more about Bone Therapeutics Appoints Thomas Lienard as Chief Business Officer

Bone Therapeutics’ ALLOB® receives Orphan Drug Designation for Osteogenesis Imperfecta from the EMA and FDA

Read more about Bone Therapeutics’ ALLOB® receives Orphan Drug Designation for Osteogenesis Imperfecta from the EMA and FDA

Subscribe to Press Releases